An Intermediate-Size Expanded Access Protocol for Amyotrophic Lateral Sclerosis with Pridopidine
使用普利多匹定治疗肌萎缩侧索硬化症的中型扩展治疗方案
基本信息
- 批准号:10835282
- 负责人:
- 金额:$ 1013.62万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-25 至 2027-08-31
- 项目状态:未结题
- 来源:
- 关键词:ALS patientsAffectAge of OnsetAgonistAmyotrophic Lateral SclerosisAutophagocytosisBiologicalBiological MarkersBrainBrain StemCell NucleusClinicalClinical DataClinical TrialsDataDiseaseDisease ProgressionDoseDouble-Blind MethodEligibility DeterminationEndoplasmic ReticulumEnrollmentEnsureEnteral FeedingFDA approvedGenetic PolymorphismGeographyGoalsHumanHuntington DiseaseIndividualLightMeasuresMembraneMethodsMitochondriaModelingMolecularMotorMotor NeuronsMutationNeuronal InjuryOralOral AdministrationOral cavityOutcomeOutcome MeasureParticipantPathway interactionsPatient Outcomes AssessmentsPatientsPersonsPharmaceutical PreparationsPharmacotherapyPhasePhenotypePhysical FunctionPlacebo ControlPopulationPropertyProteinsProtocols documentationPsychometricsQuality ControlQuality of Life AssessmentRandomizedRandomized, Controlled TrialsReceptor ActivationReceptor GeneRegimenResearchRespiratory physiologyRiluzoleRunningSafetySerumSignal TransductionSiteSpeechTestingTherapeuticVital capacityclinical efficacydesigndisabilityefficacy clinical trialefficacy studyefficacy trialendoplasmic reticulum stressgenetic analysishealthy volunteerimprovedknock-downlongitudinal datasetloss of functionmouse modelneurofilamentneuroimagingnovelnucleocytoplasmic transportopen labelpatient orientedphenylmethylpyrazoloneprimary endpointrandomized, clinical trialsreceptorreceptor functionremote assessmentresearch clinical testingsigma-1 receptorsmall moleculesmartphone applicationstandard of caresuperoxide dismutase 1therapeutic targettrendtrial design
项目摘要
The Sigma 1 Receptor (S1R) has emerged as an attractive therapeutic target in ALS.
Mutations in the S1R are causative of ALS and the degree of loss of function in S1R protein
determines age of onset. S1R knock-down exacerbates phenotypes in ALS mouse models, and
S1R activation impacts pathways that are known to be implicated in ALS, i.e., nucleocytoplasmic
transport, protein quality control, endoplasmic reticulum (ER) stress, mitochondrial function, and
autophagy. Riluzole, edaravone, and PB-TURSO, the current standard-of-care medications for
ALS in the US, offer only modest clinical benefit and are not known to act through the S1R.
Nuedexta, a non-selective S1R agonist, is approved for the treatment of pseudobulbar affect and
has been shown to improve bulbar function in a subset of people living with ALS.
Pridopidine (Prilenia Therapeutics) is a potent and highly selective small molecule S1R
agonist. The S1R shows high expression throughout the brain, particularly in brainstem motor
nuclei. In the G93A SOD1 ALS mouse model, pridopidine modified disease progression.
The safety and efficacy of pridopidine are currently being tested inthe HEALEY ALS Platform
Trial. The trial design includes an efficacy randomized controlled trial (RCT) followed by an open
label extension (OLE). The RCT portion of the pridopidine regimen enrolled 162 ALS participants.
While it did not reach the primary endpoint, it showed trends toward beneficial effects of
pridopidine on several outcome measures, with the greatest identifiable effect on functional
scores, quantitative motor speech, and neurofilament light levels in early and faster progressing
participants. The OLE is ongoing. A second efficacy trial targeting a selected population of people
with ALS is being planned. Unfortunately, a large segment of the real-world ALS population won’t
be eligible to enroll in this second efficacy study due to the restrictive eligibility criteria.
The current proposal is an expanded access protocol (EAP) of pridopidine in 200
individuals with ALS who are ineligible for clinical trials. Participants would receive
pridopidine for up to 24 months, while the OLE and the planned second efficacy trial are ongoing.
This study will provide real- world data by evaluating the effects of the drug in a population
that is broader than the one included in the efficacy trials and by collecting safety, clinical,
and biological outcomes over longer term exposure.
Sigma-1受体(S1R)已成为ALS治疗的重要靶点。
S1R基因突变是ALS和S1R蛋白功能丧失程度的原因
决定发病年龄。S1R基因敲除加剧了ALS小鼠模型的表型,并且
S1R激活影响已知的与ALS有关的通路,即核质
运输、蛋白质质量控制、内质网(ER)应激、线粒体功能和
自噬。利鲁唑、依达拉奉和PB-Turso,目前的标准护理药物
在美国,肌萎缩侧索硬化症只提供温和的临床益处,并不知道通过S1R起作用。
NUEDEXTA是一种非选择性S1R激动剂,被批准用于治疗假性延髓影响和
已被证明可以改善部分ALS患者的延髓功能。
普里多巴定(Prilenia Treeutics)是一种高效、高选择性的小分子S1R
激动剂。S1R在整个大脑中都有高表达,特别是在脑干运动中
原子核。在G93A SOD1ALS小鼠模型中,普里多巴定改善了疾病进展。
普立多巴胺的安全性和有效性目前正在Healey ALS平台上进行测试
审判。试验设计包括一项有效性随机对照试验(RCT),随后是一项开放试验
标签扩展(OLE)。普立多巴定方案的RCT部分招募了162名ALS参与者。
虽然它没有达到主要终点,但它显示出以下有益效果的趋势
普鲁多巴定在几个结果指标上,对功能的影响最大
早期和较快进展的分数、量化运动语言和神经细丝光照水平
参与者。OLE正在进行中。针对选定人群的第二次疗效试验
与肌萎缩侧索硬化症的关系正在计划之中。不幸的是,现实世界中的很大一部分ALS人群不会
由于严格的资格标准,有资格参加这项第二次疗效研究。
目前的建议是200中的普立多巴胺的扩展访问协议(EAP)
没有资格参加临床试验的肌萎缩侧索硬化患者。参与者将收到
最长可达24个月,而OLE和计划中的第二次疗效试验正在进行中。
这项研究将通过评估药物在人群中的效果来提供真实世界的数据
这比包括在疗效试验中的数据更广泛,通过收集安全性、临床和
以及长期暴露的生物学结果。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Suma Babu其他文献
Suma Babu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Suma Babu', 18)}}的其他基金
Intermediate-Size Expanded Access Trial of Autologous Hybrid TREG/Th2 Cell Therapy (RAPA-501) of Amyotrophic Lateral Sclerosis
肌萎缩侧索硬化症自体杂交 TREG/Th2 细胞疗法 (RAPA-501) 的中型扩大试验
- 批准号:
10834469 - 财政年份:2023
- 资助金额:
$ 1013.62万 - 项目类别:
An Expanded Access Protocol of Intravenous Trehalose Injection 90 mg/mL Treatment of Patients with Amyotrophic Lateral Sclerosis
静脉注射海藻糖注射液 90 mg/mL 治疗肌萎缩侧索硬化症的扩展方案
- 批准号:
10649756 - 财政年份:2022
- 资助金额:
$ 1013.62万 - 项目类别:
相似海外基金
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
$ 1013.62万 - 项目类别:
Training Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
$ 1013.62万 - 项目类别:
Standard Grant
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
$ 1013.62万 - 项目类别:
Standard Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
$ 1013.62万 - 项目类别:
Fellowship
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
$ 1013.62万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
$ 1013.62万 - 项目类别:
Research Grant
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
$ 1013.62万 - 项目类别:
Studentship
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
$ 1013.62万 - 项目类别:
Operating Grants
New Tendencies of French Film Theory: Representation, Body, Affect
法国电影理论新动向:再现、身体、情感
- 批准号:
23K00129 - 财政年份:2023
- 资助金额:
$ 1013.62万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The Protruding Void: Mystical Affect in Samuel Beckett's Prose
突出的虚空:塞缪尔·贝克特散文中的神秘影响
- 批准号:
2883985 - 财政年份:2023
- 资助金额:
$ 1013.62万 - 项目类别:
Studentship